Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
1 of 4
http://www.pharmaphorum.com/2012/08/30/a-history-of-glaxosmithkline/
Username
Remember Me
Home
Articles
Articles
Showcase
Jobs
Events
Disease Area
A history of GlaxoSmithKline
Forums
Events
About us
Interviews
Search Articles
Contact
News
R&D
Share |
Hannah Blake
pharmaphorum
Two years ago, we ran a series called A history of, which took an in-depth
Related Articles
Rare diseases part 1: posin...
0 comments
companies. Assistant Editor, Hannah Blake, picks this series back up, starting
0 comments
ahead...
look at the history of the pharmaceutical industry and some of the top pharma
1 comment
Recent Topics
Profitable companies
20th November
should...
number of different name changes, before it became the GSK we know today.
Alliances in bio-pharaceuti...
So how did this pharmaceutical company become so successful?
Introduction !!!!!
25th October
18th September
Recent News
8th March
8th March
8th March
2013-2...
Around the same time, Thomas Beecham launched the Beechams Pills laxative business in England. In 1859,
Beecham opened a factory in St Helens, which was the worlds first factory to be built solely for making medicines.
Upcoming Events
This wasnt the only first in 1887, Beechams factory was the first in the area to have electricity.
Russian & CEE Pharma Ma...
Meanwhile in New Zealand, Englishman Joseph Nathan establishes a general trading company called Joseph
Nathan & Co. By 1904, the company began exporting dried milk powder to London, which was trademarked as
Progr...
Glaxo two years later. In 1908, the Glaxo department of Joseph Nathan & Co opened in London.
Back in the USA, Smith Kline and Company increased its portfolio of consumer brands by acquiring French,
Richards and Company. In 1910, a range of iron tablets, lozenges and poison ivy lotion, called the Blue Line, was
added to the company then called Smith, Kline and French. Nine years later, Mahlon Kline began sending
pharmaceutical samples through the mail to doctors across the US.
Glaxos first pharmaceutical product was the vitamin D preparation, Ostelin, in 1924. The company built new
research facilities in 1935, called Glaxo Laboratories, which absorbed Joseph Nathan & Co in 1947. In the same
year, Glaxo was listed for the first time on the London Stock Exchange.
The middle merging many into one
The 1950s signified a revolution in the treatment of mental illness, after Smith, Kline and French introduced the
anti-psychotic drug, thorazine (chlorpromazine). This drug was the product of reference in the first generation of
central nervous system drugs. In 1969, Smith, Kline and French entered the clinical laboratories business and
purchased seven laboratories in the US and one in Canada.
Between 1938 and 1972, Beecham (formerly Beechams Pills) acquired products still well-known today, such as
Macleans toothpaste, Lucozade energy-replacement drinks and mens hair application, Brylcreem. The company
10/03/2013 10:41
2 of 4
http://www.pharmaphorum.com/2012/08/30/a-history-of-glaxosmithkline/
also began a pharmaceutical research lab, called Beecham Research Laboratories and in 1945, the companies,
along with an allergy vaccines company, merged into one the Beecham Group plc.
In 1972, Beecham Group plc was unsuccessful in its bid for Glaxo Group Ltd and Glaxo was unsuccessful in its
attempt to merge with UK chemists Boots.
Glaxos business in the US began a few years later, as Glaxo Inc, through the acquisition of Meyer Laboratories
Inc. Glaxo launched anti-ulcer treatment, Zantac (ranitidine) in 1981 and becomes the worlds top-selling
medicine by 1986. Smith, Kline, French, meanwhile, became the SmithKline Corporation in 1976, and then
SmithKline Beckman in 1982, after merging with diagnostics company, Beckman Instruments.
SmithKline Beecham plc was formed in 1989, following the merger of SmithKline Beckman and the Beecham
Group plc.
Four years later, in 1993, SmithKline Beecham negotiated a multi-million dollar research collaboration agreement
with Human Genome Science, to identify and describe the functions of the genes in the human body. Around
the same time, Glaxo merged with Wellcome, a company established in the nineteenth century and built up since,
to become Glaxo Wellcome. The Queen opens Glaxo Wellcomes Medicines Research Centre in Stevenage.
SmithKline Beecham also collaborated with the World Health Organisation in 1998, to eliminate lymphatic
filariasis (elephantiasis) by the year 2020. In 1999, the company launched Avandia (rosiglitazone maleate), for
the treatment of type2 diabetes, in the US.
The GSK we know today
It would have made chronological sense to name this chapter, The End, but its fair to say that GSK will continue
to grow and develop, and no one knows if this will bring further name changes and directions. But anyway, back
to the story
In 2000, the year of the millennium, Glaxo Wellcome and SmithKline Beecham merged to form the name we
know today, GlaxoSmithKline.
Since then, GSK has continued to work with other organisations to fight some of the biggest diseases around the
world.
In the same year as the merger, GSK made a pledge that it would provide three HIV / AIDS medicines to
developing country governments at significant price reductions. By the end of 2002, GSK had secured 120
arrangements to supply these medicines to 50 of the worlds poorest country and in 2004, it shipped 33 million
tablets of HIV treatment, combivir, to Africa.
GSK launched the African Malaria Partnership in 2001, boosting the global awareness of the disease that kills over
one million people every year. Bill Gates, founder of the Bill & Melinda Gates Foundation highlights GSK in
recognition of the companys commitment to R&D on malaria, five years later in 2005.
The company has also continued to work with the WHO in its fight to combat lymphatic filariasis, and even
donated the first 100 million of its albendazole tablets. On th July 2003, ten million people in Sri Lanka received
these free doses. By the end of 2006, GSK had donated 600 million treatments, and found itself as the recipient of
the New Business Award.
GSK has also been on hand when natural disasters have struck, donating medicines and vaccines following the
Tsunami disaster of December 2004, after the damage caused in the USA by Hurricane Katrina in 2005 and also
following the Haiti earthquake in 2010.
Andrew Witty succeeded JP Garnier as Chief Executive Officer (CEO) in 2008.
Over the years, GSK has continued to research and develop new treatments and acquire new products. From
cervical cancer vaccine, cervarix, to the first-ever FDA-approved obesity treatment, alli, to the oral treatment,
requip XL, for Parkinsons disease, GSK has been at the forefront of providing medicines to billions of people
across the globe since its humble beginnings in the 19th century.
However, things havent always gone to plan. In July 2012, GSK was fined US $3 billion in the biggest
healthcare fraud case in history, after promoting two antidepressant drugs for unapproved uses.
10/03/2013 10:41
3 of 4
http://www.pharmaphorum.com/2012/08/30/a-history-of-glaxosmithkline/
In what some might say as ironic, two weeks later GSK were named as the Official Laboratory Services
Provider for the London 2012 Olympic and Paralympic Games. Following the Games, the facility will become the
UKs first phenome-research centre.
th
As of July 6 2012, GSK had the fifth-largest market capitalisation on the London Stock Exchange with a total of
74.8 billion. GSKs primary listing is on the London Stock Exchange, but it also has a secondary listing on the
New York Stock Exchange.
So, whats next?
Its hard for anyone to predict the future, but during the early 2000s, GSK began many long-term projects and
collaborations, which will most likely begin to yield results in the next decade or so.
Advances in technology will also continue to pressure GSK, and other pharmaceutical companies, into finding
more sufficient treatments and vaccines. In 2011, nearly 600 million was invested into the R&D of vaccines by
GSK and over 1,600 scientists are currently working on the development of vaccines alone, with a further 12,500
people working in research teams in the UK, USA, Spain, Belgium and China to develop treatments.
GSK also has a long-term vision to make its entire value chain carbon neutral by 2050.
References
http://www.gsk.com/
http://en.wikipedia.org/wiki/GlaxoSmithKline
http://www.gskvaccines.com/
http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=GSK:LSE
Previous A history of articles:
A history of the pharmaceutical industry
A history of Amgen
A history of Pfizer
A history of contract research organisations (CROs)
The next A history of article will be published on the 27th September.
Post Comment
Comments are moderated, and will not appear until approved by a member of the pharmaphorum team.
You must be logged in to post a comment.
Website and content copyright 2009-2013, pharmaphorum media limited or its licensors; all rights reserved.
10/03/2013 10:41
4 of 4
http://www.pharmaphorum.com/2012/08/30/a-history-of-glaxosmithkline/
10/03/2013 10:41